Exciting news regarding our licensee, Dermata Therapeutics, LLC, a biotechnology company developing new and innovative products to treat a variety of dermatological diseases, announces dosing the first patient with its lead compound DMT210, in a Phase 2 acne rosacea study. DMT210, (formerly Signum's SIG-990 molecule) is a topical gel specifically developed to downregulate the proinflammatory cytokines in the skin responsible for the inflammation and redness seen in acne rosacea.   Full Press Release

Subscribe Here!

Benjamin Stock

Written by Benjamin Stock

Ben is a Marketing Associate here at Signum Biosciences, and has been working on social media, website content, video content, and anything else he can get his hands on. In addition to his passion for creating content, Ben is outside as much as possible in the health and fitness hub that is Boulder, CO.